ImmusanT Announces Initiation of Phase 2 Clinical Trial of Therapeutic Vaccine for Celiac Disease
ImmusanT, Inc., announces first patient dosed in Phase 2 clinical trial, RESET CeD, testing the safety and efficacy of Nexvax2®, a therapeutic vaccine for the treatment of celiac disease patients.
Continue Reading